NCT04586725

Brief Summary

Peripheral artery disease (PAD) is characterised by a build up of fatty plaque in the arteries in the lower limbs, resulting in a reduction of blow flow to the muscles. Globally, it is estimated that 236 million people are living with PAD. A classic symptom of PAD is intermittent claudication (IC) which is characterised by muscle cramps in the lower limbs, typically brought on by exercise and relieved at rest. Exercise is recommended at first line treatment for IC. However to assess IC symptoms in response to an exercise study, maximal walking capacity (the furthest they can walk before it becomes too painful to walk) is typically the main measure. A patients walking capacity is assessed by a number of exercise testing protocols including the six-minute walk test (6MWT), where patients walk for six minutes with the aim to walk as far as they can in the time allotted. Patient encouragement has been shown to improve walking performance by as much as 30 meters in heart failure and respiratory disease populations. However the effect of encouragement on walking performance in people with IC is yet to be studied.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
76

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2021

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 7, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 14, 2020

Completed
12 months until next milestone

Study Start

First participant enrolled

October 1, 2021

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
Last Updated

August 4, 2021

Status Verified

July 1, 2021

Enrollment Period

2.2 years

First QC Date

October 7, 2020

Last Update Submit

July 28, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Maximal walking distance (MWD)

    Metres walked during the tests

    6 weeks

Secondary Outcomes (1)

  • Learning effect metres walked

    6 weeks

Study Arms (2)

Encouragement every minute

ACTIVE COMPARATOR

Patients will be randomised to six tests at one week apart

Other: Encouragement a one minute intervalsOther: Encouragement a two minute intervals

Encouragement every two minutes

ACTIVE COMPARATOR

Patients will be randomised to six tests at one week apart

Other: Encouragement a one minute intervalsOther: Encouragement a two minute intervals

Interventions

Patients will perform the six exercise tests with encouragement at one minute intervals

Encouragement every minuteEncouragement every two minutes

Patients will perform the six exercise tests with encouragement at two minute intervals

Encouragement every minuteEncouragement every two minutes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \>18 years old
  • Resting ankle brachial pressure index (ABPI) \<0.9 or a reduction of ≥ 20 mmHg following exercise testing (per site protocol)
  • Able to walk unaided
  • English speaking and able to follow exercise instructions
  • Able to provide informed consent

You may not qualify if:

  • Those who have critical limb threatening ischaemia (rest pain and/or tissue loss)
  • Unable to provide consent
  • Those presenting with any significant comorbidities or contraindications to exercise testing or training in accordance to the American College of Sports Medicine
  • Uncontrolled or symptom limiting coronary heart or pulmonary disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Intermittent Claudication

Condition Hierarchy (Ancestors)

Peripheral Arterial DiseasePeripheral Vascular DiseasesVascular DiseasesCardiovascular DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Stefan Birkett, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Participants will be blinded to the level of encouragement they will receive during the tests
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer In Exercise Science

Study Record Dates

First Submitted

October 7, 2020

First Posted

October 14, 2020

Study Start

October 1, 2021

Primary Completion

December 1, 2023

Study Completion

January 1, 2024

Last Updated

August 4, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share